# Week of May 16 – 20, 2022

## OUHSC DEPARTMENT OF MEDICINE CONFERENCE SCHEDULE

**NOTE: All CME conferences will be designated by an \* by the name of the conference.**

|  |  |
| --- | --- |
| **Monday, May 16, 2022** |  |

12:15 – 1:00 PM Medicine House Staff Conference: “Resident Talk,” Sowmya R. Srimanthula, MD, Medicine/Pediatric Resident. AAT Conf Rm A&B

12:15 – 1:15 PM Pulmonary and Critical Care Conference: “Essential Maternal Physiology for the Critical Care Physician,” Pavan Parikh, MD, Assistant Professor, Department of Obstetrics and Gynecology. AAT 8200

|  |  |
| --- | --- |
| **Tuesday, May 17, 2022** |  |

7:15 – 8:00 AM Cardiology Cath Conference: Case Presentation. AAT 5200 or Zoom Meeting

8:00 – 9:00 AM Endocrinology Clinical Journal Club: “Diabetes Type 2,” Jonea Lim, MD, Associate Professor, Department of Medicine/Endocrinology. HHDC 2923

Learning Objectives: Upon completion of this session, participants will improve their competence and performance by being able to: Review and discuss recent clinical research articles and apply those findings to daily practice.

12:15 – 1:15 PM **\***Medicine Grand Rounds: “Updates on Diagnosis and Management of Thrombotic Thrombocytopenic Purpura (TTA)” Azra Borogovac, MD, MS, Assistant Professor, Department of Medicine/Hematology-Oncology. Available by Zoom Meeting ID: 915 6165 6346 Passcode: 90357946 <https://zoom.us/j/91561656346?pwd=bmoxQVU0TTZCSjlSbTdXYUY3MFV0QT09> or join us by phone, 1-602-753-0140 (1.00 *AMA PRA Category 1 Credit™)*

Professional Practice Gap: Gap 1: Practitioners have difficulty recognizing and diagnosing thrombotic microangiopathy (TMA) syndromes. Gap 2: Practitioners may not be aware of the long-term outcomes and current treatment options in patients with immune-mediated and hereditary TTP.

Learning Objectives: Upon completion of this session, participants will improve their competence and performance by being able to: Recognize and develop a differential diagnosis when encountering thrombotic microangiopathy. Employ appropriate work-up and treatment for suspected TTP. Review long-term neurologic and psychiatric effects of immune-mediated and hereditary TTP. Review mechanism of action, safety and efficacy of novel agents used in the management of TTP.

Speaker Disclosure: Dr. Borogovac has no relevant financial relationships or affiliations with commercial interests to disclose.

|  |  |
| --- | --- |
| **Wednesday, May 18, 2022** |  |

7:00 – 8:00 AM Vascular Conference: AAT 9200

7:15 – 8:00 AM Cardiology Journal Club/Faculty Wheelhouse Lecture: AAT 5200

8:15 – 9:00 AM ID Case Conference: AAT Conf Rm C

12:15 – 1:00 PM Medicine House Staff Conference: Wellness Day. AAT Conf Rm A&B

12:15 – 1:15 PM Pulmonary and Critical Care Conference: Instructive Case Conference. AAT 8200

1:30 – 2:30 PM Renal Grand Rounds: Case Consultation: AAT 5328

1:30 – 3:30 PM Rheumatology Clinical Conference: “Fellow’s Conference,” Rabia Cheema, MD, Rheumatology/Immunology/Allergy Fellow. AAT Conf Rm, 1st Fl, Rm B

3:00 – 4:00 PM GI Quality Improvement Projects: SEC 3rd Fl Conf Rm

4:00 – 5:00 PM GI Pathology Conference: SEC 3rd Fl Conf Rm

**Department of Medicine Conference Schedule May 16 - 20, 2022**

|  |  |
| --- | --- |
| **Thursday, May 19, 2022** |  |

7:15 – 8:00 AM Cardiovascular Grand Rounds: “Lipoprotein(a): Unveiling the Mysterious Biomarker,” Nishant Shah, MD, FACC Assistant Professor of Medicine in Cardiology, Duke Heart Center, Duke University School of Medicine, Duke Clinical Research Institute. Zoom Meeting ID 977 4484 5776 Passcode: 12345678

<https://zoom.us/j/97744845776?pwd=WHkvVnpya3N0TlhhQ0cyNm03RFZ2Zz09>

Professional Practice Gap: While it is known that Lipoprotein(a) [Lp(a)] contributes to the development of vascular disease, there is still uncertainty regarding whether or not Lp(a) should be assessed routinely as a risk enhancer. Moreover, many cardiovascular professionals may be unsure about who to screen and how knowing Lp(a) levels could change patient management.

Learning Objectives: Upon completion of this session, participants will improve their competence and performance by being able to: Discuss the genetic make-up for Lp(a). Enumerate who to screen for Lp(a). Discuss current and future management strategies for elevated Lp(a).

12:15 – 1:00 PM Medicine House Staff Conference: “Resident Talks,” Khawaja Akhtar, MD, Medicine Resident and Saytam Krishan, MD, Medicine Resident. AAT Conf Rm A&B

12:15 – 1:15 PM Pulmonary and Critical Care Conference: “Neuro ICU-Subarachnoid Hemorrhage – Initial Management and ICU Care,” Uttam Verma, MD, Assistant Professor, Department of Neurology. AAT 8200

|  |  |
| --- | --- |
| **Friday, May 20, 2022** |  |

7:15 – 8:00 AM Echocardiography Conference: AAT 5200

12:15 – 1:00 PM Medicine House Staff Conference: Social Justice. AAT Conf Rm A&B

12:15 – 1:15 PM Pulmonary and Critical Care Conference: National Conference Attendee Report. AAT 8200

1:30 – 2:30 PM Combined Thoracic-Oncology Clinical Care Conference: VAMC 5F-121

For accommodations on the basis of disability, call 405-271-6655 x1.

FUTURE EVENTS

May 30 Memorial Day 2022

### Check out the Internet listing of grand rounds and seminars at: <http://www.ouhsc.edu/insidehsc/>

To place name on mailing list or provide input for future schedules, contact Ms. Brenda Wilkerson, Department of Medicine. Schedules are typically e-mailed on Thursday of the week prior to the week of listed activities. If you wish to receive this via e-mail, you may use the Internet to request it. Address: [Brenda-Wilkerson@ouhsc.edu](mailto:Brenda-Wilkerson@ouhsc.edu)

**Accreditation Statement:** The University Of Oklahoma College Of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Mitigation Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

**Acknowledgement of Commercial and In-Kind Support:** Commercial support is financial, or in-kind, contributions given by an ineligible company, which is used to pay all or part of the costs of a CME activity.  An ineligible company is any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity received no commercial or in-kind support.

**University of Oklahoma Equal Opportunity Statement / Non-Discrimination Statement:**The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides.

To file a grievance related to the non-discrimination policy, report sexual misconduct, and/or file a formal complaint of sexual misconduct, please utilize the reporting form at [link.ou.edu/reportingform](file:///\\dch-comd1\do\ocpd\22D%20RSS%202021-2022\22D%20To%20Do\link.ou.edu\reportingform).

Inquiries regarding non-discrimination policies may be directed to the Office(s) of Institutional Equity as may be applicable – Norman campus: (405) 325-3546/3549, Health Sciences Center: (405) 271-2110, or OU-Tulsa Title IX Office: (918) 660-3107. Additionally, individuals may visit [www.ou.edu/eoo](http://www.ou.edu/eoo).

**Accommodations Statement:** For accommodations, please contact the Dept. of Medicine at 405-271-6651 ext. 1.

**Policy on Planner and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also discloses discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s).

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Disclosure & Mitigation Report**

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its accredited CE activities.  We have implemented a process where everyone who is in a position to control the content of an educational activity has identified to us all financial relationships with ineligible companies. In addition, should it be determined that a relevant financial relationship exists, this must be mitigated prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CE planners and presenters and ineligible companies for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity’s disclosure and mitigation information.

|  |  | | **Nature of the Financial Relationship** | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Role** | **First Name** | **Last Name** | **Commercial Interest** | | **What was received?** | **For what role?** |
| Planning Committee/ Presenter | Adam S. | Asch, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | | |
| Planning Committee/ Presenter | Mary Zoe | Baker, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | | |
| Presenter | Azra | Borogovac, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | | |
| Course Director/ Moderator | Michael S. | Bronze, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | | |
| Planning Committee/ Presenter | Brent R. | Brown, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | | |
| Planning Committee/ Presenter/ Moderator | Benjamin D. | Cowley, Jr, MD | Otsuka | Consultant Fee | | Monitoring Committee, Trial |
| **Planner:** Dr. Cowley has recused himself from planning content in the conflicted area. **Moderator:** Dr. Cowley will limit his role to the introduction of presenters, fielding questions, and moderating the flow of discussion between participants and presenters. **Presenter:** The conflict was resolved by Dr. Cowley agreeing to only present peer-reviewed, published data and recommendations that have been previewed by the OU CPD office. | | | | | | |
| Planning Committee / Presenter / Moderator | Douglas A. | Drevets, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | | |
| Planning Committee | Courtney W. | Houchen, MD | COARE Biotechnology | Grants/Research | | Co-Founder |
| **Planner:** Dr. Houchen has recused himself from planning content in the conflicted area. | | | | | | |
| Planning Committee / Presenter | Mary Beth | Humphrey, MD, PhD | I have no financial relationships or affiliations with ineligible companies to disclose. | | | |
| Planning Committee | Rhett L. | Jackson, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | | |
| Planning Committee | Lee A. | Jennings, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | | |
| Planning Committee / Presenter | Dwight W. | Reynolds, MD | Medtronic, Inc | Honorarium | | Speaker, Advisory Board |
| Medtronic, Inc | Research Funding | | Primary Investigator |
| **Planner:** Dr. Reynolds has recused himself from planning content in the conflicted areas. **Presenter:** The conflict was resolved by Dr. Reynolds agreeing that the presentation(s) will not include discussion of any products or services from the commercial interests. | | | | | | |
| Course Contact | Brenda E. | Wilkerson | I have no financial relationships or affiliations with ineligible companies to disclose. | | | |